San Diego
,
US
23 - 26 June 2023
American Diabetes Association’s 83rd Scientific Sessions (ADA 2023)
Presentation schedule and materials
Friday, 23 June 2023
14:30
- 14:45
PDT
53-OR
ORAL PRESENTATION
Efficacy and Safety of Co-Administered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes
Juan P. Frias1; Srikanth Deenadayalan2; Lars Erichsen2; Filip K. Knop3,4,5; Ildiko Lingvay6; Stanislava Macura2; Chantal Mathieu7; Sue D. Pedersen8; Melanie J. Davies9
14:45
- 15:00
PDT
54-OR
ORAL PRESENTATION
Effect of Co-administered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM
Chantal Mathieu1; Srikanth Deenadayalan2; Lars Erichsen2; Juan Frias3; Filip K. Knop4,5,6; Ildiko Lingvay7; Eva Winning Lehmann2; Sue D. Pedersen8; Melanie J. Davies9
18:30
PDT
200-LB
POSTER
Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes
Bochra Zareini1; Thomas Gerds2; Kathrine Kold Sørensen1; Kim K. B. Clemmensen3,4; Kajsa Kvist3; Jens-Peter David3; Christian Torp-Pedersen1
18:30
PDT
803-P
POSTER
Superior glycemic control with once-weekly insulin icodec with a dosing guide app vs once-daily basal insulin analogs in insulin-naïve type 2 diabetes: ONWARDS 5
Harpreet S. Bajaj1; Jens Aberle2; Melanie Davies3; Anders Meller Donatsky4; Marie Frederiksen4; Dilek Gogas Yavuz5; Amoolya Gowda4; Ildiko Lingvay6; Bruce Bode7
18:30
PDT
85-LB
POSTER
CGM-based metrics and CGM-derived hypoglycemia duration with once-weekly insulin icodec versus once daily insulin glargine U100 in insulin-naive T2D: ONWARDS 1 post hoc analyses
Richard Bergenstal1; Sara Kehlet Watt2; Ana Laura De Souza Almeida Matos2; Ildiko Lingvay3; Julia K. Mader4; Tomoyuki Nishida5; Julio Rosenstock6
18:30
PDT
804-P
POSTER
Similar hypoglycemia duration with once-weekly insulin icodec versus degludec or glargine U100 in insulin-treated T2D: a post hoc CGM analysis from ONWARDS 2 and 4
Harpreet S. Bajaj1; Björg Ásbjörnsdóttir2; Lisbeth Carstensen2; Christian Laugesen2; Chantal Mathieu3; Athena Philis-Tsimikas4; Tadej Battelino5
18:30
PDT
87-LB
POSTER
REal-World Impact of Once-Weekly Injectable Semaglutide on GLycemic Control and Weight Outcomes in Type 2 DiAbeTEs (RELATE – OW Injectable Semaglutide)
James Amamoo1; Riddhi P. Doshi2; Joshua Noone1; Xi Tan1; Lin Xie1; Cory L. Gamble1; Mico Guevarra1; Justin Chen2; Aaron A. King3
18:30
PDT
76-LB
POSTER
Glucagon-like peptide-1 receptor agonist (GLP-1RA)-experienced adults with type 2 diabetes (T2D) switching to once-weekly (OW) semaglutide in a real-world setting: SURE program post hoc analysis
Gottfried Rudofsky1; Markus Menzen2; Louis Potier3; Andrei-Mircea Catarig4; Alice Clark4; Prachi Priyadarshini5; Cristina Abreu6
18:30
PDT
791-P
POSTER
Comparing the real-world effects of once-weekly GLP-1 RAs and DPP-4is on ischemic stroke and myocardial infarction in individuals with T2D and ASCVD
Xi Tan1; Yuanjie Liang1; Jigar R. Rajpura1; Larisa Yedigarova1; Josh Noone1; Lin Xie1; Adam de Havenon2
MATERIALS AVAILABLE
18:30
PDT
795-P
POSTER
Elucidating the role of weight loss and glycemia with observed benefits of GLP-1 receptor agonist treatment in patients with T2D
Anukriti Sharma1,2; Arshiya Mariam1,2; Emily Zacherle3; Alex Milinovich1; Janine Bauman1; David S. Sugano1; Josh Noone3; Jigar R. Rajpura3; Robert S. Zimmerman4; Bartolome Burguera4; Michael W. Kattan1; Anita D. Misra-Hebert1; Kevin M. Pantalone4; Daniel M. Rotroff1,2,4
18:30
PDT
86-LB
POSTER
REal-World Impact of Oral Semaglutide on GLycemic Control and Weight Outcomes in Type 2 DiAbeTEs (RELATE – Oral Semaglutide)
James Amamoo1; Riddhi P. Doshi2; Joshua Noone1; Xi Tan1; Lin Xie1; Cory L. Gamble1; Mico Guevarra1; Justin Chen2; Aaron A. King3
18:30
PDT
790-P
POSTER
An Indirect Treatment Comparison of the cardiovascular protective effect of semaglutide vs liraglutide in subjects with T2D
Barrie Chubb1; Martin Bøg1
18:30
PDT
780-P
POSTER
Occurrence of gastrointestinal (GI) side effects upon GLP-1 receptor agonist (GLP-1RA) initiation with concomitant metformin use
Klara R. Klein1; Kim K. B. Clemmensen2,3; Edwin Fong2; Søren Olsen2; Trine Abrahamsen2: Ildiko Lingvay4
18:30
PDT
776-P
POSTER
Comparative Effectiveness of Subcutaneous Semaglutide in Adults with Type 2 Diabetes in US Routine Clinical Practice – Year 1 Results of SePRA, a Randomized Pragmatic Clinical Trial
John Buse1; Ben Soule2; Brian Harty3; Helene Nordahl Christensen2; Mark Cziraky4; Vincent Willey4; Simon Skibsted5
18:30
PDT
809-P
POSTER
The effect of various degrees of hepatic impairment on the pharmacokinetic characteristics of once-weekly insulin icodec
Hanne Haahr1; Blanka Cieslarova2; Anders M Donatsky1; Josmin R Joseph3; Niels R Kristensen1; Viera Kupčová4; Janne R Hingst1
18:30
PDT
816-P
POSTER
Predictors of Adherence and Persistence to Basal Insulin Therapy in Adults with Type 2 Diabetes
Vanita R. Aroda1; Nick Fabrin Nielsen2; Kamal Kant Mangla2; Yi Wang3; Tarlan Namvar4; Jigar Rajpura4
18:30
PDT
201-LB
POSTER
Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes
Bochra Zareini1; Thomas Gerds2; Kathrine Kold Sørensen1; Kim K. B. Clemmensen3,4; Kajsa Kvist3; Jens-Peter David3; Christian Torp-Pedersen1
18:30
PDT
1001-P
POSTER
Adherence and Persistence to Basal Insulin Therapy is Associated with Decreased Healthcare Utilization in Adults with Type 2 Diabetes
Nick Fabrin Nielsen1; Vanita R. Aroda2; Kamal Kant Mangla1; Victoria Divino3; Tarlan Namvar4; Jigar Rajpura4
MATERIALS AVAILABLE
18:30
PDT
810-P
POSTER
Do people living with T1D use the dosing flexibility of degludec and does this depend on patient characteristics?
Yvonne Winhofer1; Anne Kaas2; Nikoline Nygård Knudsen2; Johannes Handberg Juul Martiny2; Chantal Mathieu3
18:30
PDT
815-P
POSTER
Enhanced Disulphide Bond Stability Contributes to the Once Weekly PD Profile of Insulin Icodec
František Hubálek1; Christian Cramer1; Hans Helleberg1; Eva Johansson1; Gerd Schluckebier1; Dorte B. Steensgaard1; Jeppe Sturis1; Thomas Kjeldsen1
18:30
PDT
746-P
POSTER
Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint
Linong Ji1; Andrew J Ahmann2; Bo Ahrén3; Matthew S Capehorn4; Ping Hu5; Ildiko Lingvay6; Wenyan Liu5; Helena Rodbard7; Zewei Shen5; Christopher Sorli8
18:30
PDT
808-P
POSTER
Pharmacokinetic properties of once-weekly insulin icodec in individuals with renal impairment vs normal renal function
Hanne Haahr1; Niels R Kristensen1; Jonas H Larsen2; Frank-Dietrich H Wagner3; Stanislav Ignatenko3
18:30
PDT
797-P
POSTER
Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D
Jean-Francois Yale1; Atheline Major-Pedersen2; Andrei-Mircea Catarig3; Rashmi Jain4; Markus Menzen5; Patrick Holmes6
Saturday, 24 June 2023
13:45
- 14:00
PDT
178-OR
ORAL PRESENTATION
Once-weekly insulin icodec versus once-daily insulin degludec in insulin-naive type 2 diabetes. ONWARDS 3: a head-to-head, double-blind study
Ildiko Lingvay1; Marisse Asong2; Cyrus Desouza3; Pierre Gourdy4; Soumitra Kar5; André Vianna6; Tina Vilsbøll7,8,9; Siri Vinther2; Yiming Mu10
14:00
- 14:15
PDT
179-OR
ORAL PRESENTATION
Improved A1C and TIR with Once-Weekly Insulin Icodec versus Insulin Glargine U100 in Insulin-Naïve T2D: ONWARDS 1
Julio Rosenstock1; Stephen C. Bain2; Amoolya Gowda3; Esteban Jodar4; Bo Liang3; Ildiko Lingvay5; Tomoyuki Nishida6; Roberto Trevisan7; Ofri Mosenzon8
Sunday, 25 June 2023
14:00
- 14:15
PDT
275-OR
ORAL PRESENTATION
Association between treatment adherence and CGM outcomes in people with diabetes using smart insulin pens in a real-world setting
Thomas Danne1; Niels Væver Hartvig2; Anne Kaas2; Nikoline Nygård Knudsen2; Julia K. Mader3
Keywords